T. Rowe Price Associates
AVBP icon

T. Rowe Price Associates’s ArriVent BioPharma AVBP Stock Holding History

T. Rowe Price Associates’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$522K Buy
22,593
+6,478
+40% +$146K ﹤0.01% 2438
2025
Q4 		$325K Buy
16,115
+1,760
+12% +$36.6K ﹤0.01% 2613
2025
Q3 		$265K Buy
14,355
+2,902
+25% +$57K ﹤0.01% 2665
2025
Q2 		$250K Sell
11,453
-1,018
-8% -$21.1K ﹤0.01% 2610
2025
Q1 		$231K Buy
12,471
+1,506
+14% +$36.9K ﹤0.01% 2573
2024
Q4 		$293K Buy
10,965
+1,620
+17% +$46.5K ﹤0.01% 2521
2024
Q3 		$220K Buy
+9,345
New +$212K ﹤0.01% 2620

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's AVBP Position: Q1 2026 in Review

T. Rowe Price Associates increased its ArriVent BioPharma (AVBP) stake by 40% in Q1 2026, buying an estimated $146K and bringing the position to 22,593 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #2438.

T. Rowe Price Associates first reported a position in AVBP in Q3 2024 and has held it in 7 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • T. Rowe Price Associates held 22,593 shares of ArriVent BioPharma worth $522K as of Q1 2026.
  • T. Rowe Price Associates bought 6,478 ArriVent BioPharma shares in Q1 2026, an estimated $146K.
  • ArriVent BioPharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2438 holding.
  • T. Rowe Price Associates first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 7 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.